Innate Pharma SA

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference being held on January 13-16, 2025 in San Francisco, CA. Jonathan Dickinson, Chief Executive Officer of Innate Pharma, will represent the Company in a session scheduled Tuesday, January 14, 2025 from 11:15 - 11:55 am PST. Other Executive Boar.

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab in the TELLOMAK Phase 2 clinical study. These data were presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The TELLOMAK study addresses a critical unmet need for p.

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

MARSEILLE, France & DIAMOND BAR, Calif.--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), together with the Institute for Follicular Lymphoma (IFLI) today announced that they have entered into an agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET® in follicular lymphoma (FL). Innate's ongoing Phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplas.

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that abstracts related to lacutamab health-related quality of life and translational data from the TELLOMAK trial and SAR443579, Sanofi-partnered ANKET® asset, have been selected for the American Society of hematology (ASH) Annual Meeting. “We are proud of the progress being made across our multiple programs, including our lead proprietary asset l.

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

Innate has a stable of interesting pipeline projects in development for a range of cancers. The most advanced candidate is poised for a potential accelerated approval for cutaneous T-cell lymphoma. Other programs, including those partnered with big pharma, are beginning to show signs of promise in non-heme malignancies as well.

Innate Pharma: Looking Like A Company We'll Regret Ignoring

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2025 financial calendar: March 27, 2025: Publication of 2024 financial statements May 13, 2025: Publication of revenue and cash position for 1Q2025 May 22, 2025: Annual General Shareholders Meeting September 17, 2025: Publication of half year financial statements November 13, 2025: Publication of revenue and cash position for 3Q2025 All financi.

Innate Pharma Releases Its 2025 Financial Calendar

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate's proprietary NK cell engager including an IL-2v and targeting CD20 from the ANKET® platform. IPH6501 is currently evaluated in a Phase 1/2 clinical trial in B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654). The data published shows that IPH65.

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

Innate Pharma S.A. (NASDAQ:IPHA ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Henry Wheeler - Vice President, Investor Relations and Communications Jonathan Dickinson - Chief Executive Officer Sonia Quaratino - Chief Medical Officer Yannis Morel - Chief Operating Officer Frederic Lombard - Chief Financial Officer Arvind Sood - Executive Vice President U.S. Operations Conference Call Participants Daina Graybosch - Leerink Partners Rajan Sharma - Goldman Sachs Arthur He - HCW Operator Hello and thank you for standing by.

Innate Pharma S.A. (IPHA) Q3 2024 Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results for the first nine months of 2024. "I'm honored to join Innate Pharma at such a pivotal moment in its evolution,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “We achieved notable regulatory milestones during the quarter including encouraging initial feedback from the FDA for lacutama.

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate (ADC) and innovative tetra-specific ANKET® will be presented at the SITC Annual Meeting 2024. “We are thrilled to share our latest preclinical data at the SITC Annual Meeting, highlighting the potential of IPH6501, our tetra-spe.

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast for third quarter 2024 results and business updates.

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming investor conferences.

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its supervisory Board has appointed Jonathan Dickinson as the Company's new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process. Jonathan Dickinson most recently served as Executive Vi.

Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to host KOL scientific symposium on immunotherapy in New York on October 3, 2024.

Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024

MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a Phase 1 clinical study of IPH4502, its novel and differentiated topoisomerase I inhibitor antibody drug conjugate (ADC) targeting Nectin-4 in solid tumors. Innate expects to initiate the Phase 1 study in the coming months. The P.

Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors

Innate Pharma S.A. (NASDAQ:IPHA ) Q2 2024 Earnings Conference Call September 12, 2024 8:00 AM ET Company Participants Henry Wheeler - Vice President, Investor Relations and Communications Herve Brailly - Interim Chief Executive Officer Sonia Quaratino - Chief Medical Officer Yannis Morel - Chief Operating Officer Frederic Lombard - Chief Financial Officer Arvind Sood - Executive Vice President U.S. Operations Conference Call Participants Rajan Sharma - Goldman Sachs Daina Graybosch - Leerink Partners Ashiq Mubarack - Citi Swayampakula Ramakanth - HCW Operator Thank you for standing by, and welcome to the Innate Pharma First-Half 2024 Financial Results and Business Update.

Innate Pharma S.A. (IPHA) Q2 2024 Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2024. The consolidated financial statements are attached to this press release. “We are focused on our growth strategy as we advance our pipeline,” said Hervé Brailly, Chief Executive Officer ad interim of Innate Pharma. “We recently presented Phase 2 results with lacutamab in myc.

Innate Pharma Reports First Half 2024 Business Update and Financial Results

AstraZeneca

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented interim results from the randomized NeoCOAST-2 (NCT05061550) Phase 2 platform study during the 2024 World Conference on Lung Cancer on September 8, 2024. The NeoCOAST-2 platform study is intended to assess the safety and efficacy of neoadjuvant durvalumab alone or combined with novel agents and chem.

Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 12, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2024. Participants during the call will be: Hervé Brailly, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice.

Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the H.C. Wainwright 26th Annual Global Investment Conference.

Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming investor conference.

Innate Pharma Announces Its Participation in Upcoming Investor Conference

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that updated efficacy and safety results from the dose-escalation part of the Phase 1/2 study with SAR443579/IPH6101 (SAR'579), an investigational CD123 targeting NKp46/CD16-based Natural Killer Cell Engager (NKCE), from a joint research collaboration between Innate Pharma and Sanofi and ANKET® platform lead asset, were shared in an oral presentat.

Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced favorable results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides (MF). The results were presented at the ASCO 2024 Annual Meeting, in Chicago, Illinois. As of October 13, 2023, data cutoff, MF patients (n=107) received a median of 4 prior systemic therapies and had a median follow-up of 11.8 months. The data demonstrate that treatme.

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that five abstracts with Innate's drug candidates have been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois. ASCO abstract details: Lacutamab Abstract: 7082 Abstract Title: Lacutamab in patients with relapsed and/or refractory mycosis fungoides: results from t.

Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2024 Annual General Meeting.

News for Innate Pharma SA Stock (IPHA)